Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Moxifloxacin HCl receptor The gene SRD A encodes the reducta
2023-07-17

The gene SRD5A2 encodes the 5-α-reductase enzyme, which converts testosterone into dihydrotestosterone. Although dihydrotestosterone levels are considerably lower than testosterone, dihydrotestosterone has a five-fold stronger binding capacity to the androgen receptor and, thereby, a considerably mo
-
Ispinesib During the year study period of men in the
2023-07-17

During the 4-year study period, 19.9% of men in the dutasteride group developed prostate cancer as compared to 25.1% in the placebo group, which represents an absolute risk Ispinesib of 5.1% for men taking dutasteride (Pe weighed against the prospect of undesirable sexual side effects and decreased
-
Our results clearly demonstrate that inhibition of ATM
2023-07-17

Our results clearly demonstrate that inhibition of ATM pathway activation results in resistance to Vγ2Vδ2 T cell-mediated cell death. Therefore, enhancing ATM activation along with Vγ2Vδ2 T cell treatment would promote the cytotoxicity of resistant ovarian cancer cells. To our knowledge, this is the
-
As previously mentioned when hypoxia treated cells become re
2023-07-17

As previously mentioned when hypoxia-treated cells become re-oxygenated they sustain a significant amount of DNA damage which has been attributed to the formation of reactive oxygen species . This finding represents more than just an interesting in vitro phenomenon as within a tumor, cells have been
-
Another factor that is involved in the severity of EAE
2023-07-17

Another factor that is involved in the severity of EAE is apoptosis signal-regulating kinase 1 (ASK1), which is one of a growing number of mitogen-activated protein kinase (MAPK) kinase kinases identified in the upstream of the c-Jun N-terminal kinase and p38 MAPK pathways [12]. We previously report
-
We have shown that an extensive region in SERBP
2023-07-17

We have shown that an extensive region in SERBP1 (amino acids 354 to 474, using co-ordinates based on the full-length isoform, Figs. 1a and 2) is necessary for it to interact with RACK1; since this region has substantial homology to the corresponding region of HABP1 (Fig. 3) it is a reasonable hypot
-
We report here the case of a patient with probable
2023-07-17

We report here the case of a patient with probable genetic prion disease with a Creutzfeldt-Jakob disease-like phenotype associated with a rare PRNP E196K mutation who initially exhibited atypical clinical manifestations principally characterized by behavioral abnormalities. Case report An 80-ye
-
br Emerging Vascular Mechanisms of
2023-07-17

Emerging Vascular Mechanisms of AA Therapy Resistance Experimental and clinical evidence indicates that physiological angiogenesis generates blood vessels capable of restoring perfusion [1], whereas tumoral angiogenesis gives rise to vessels that are structurally and functionally abnormal, therei
-
Introduction The burden of cardiovascular disease CVD is
2023-07-16

Introduction The burden of cardiovascular disease (CVD) is undisputed, accounting for approximately a third of global deaths (17.5 million people in 2012) (WHO, 2012). Atherosclerosis leads to the development of coronary heart disease (CHD) which accounts for more than 40% of these deaths (WHO, 201
-
Consistent with the in vitro results memantine ameliorated
2023-07-16

Consistent with the in vitro results, memantine ameliorated Aβ-induced cytotoxicity in rat primary cortical cultures. Studies reported that memantine protected neurons against the damage caused by aggregated Aβ40 or Aβ42 oligomers in vivo[26], [27]. These results suggest that, in addition to its neu
-
br Obstructing SNARE zippering Sharma et al demonstrated for
2023-07-16

Obstructing SNARE “zippering” Sharma et al. demonstrated for the first time that in the postmortem AD brains, the level of SNARE complex formation, which is necessary for driving synaptic vesicle fusion at the presynaptic active zone, is significantly reduced [123]. In the absence of changes in e
-
Despite clear evidence of a causative
2023-07-16

Despite clear evidence of a causative role for Aβ in AD, Aβ-mediated toxicity alone is insufficient to explain all facets of fully manifested AD. Indeed, a recent report found that two familial AD mutations in PSEN1, PSEN-L435F and PSEN-C410Y, resulted in a dysfunctional protein that does not cleave
-
Akt is another upstream kinase known to phosphorylate
2023-07-16

Akt is another upstream kinase known to phosphorylate AMPK Ser489 in response to high insulin levels [7], [21]. HepG2 pergolide show an increase in phosphorylation of AMPK at Ser485 when incubated with either insulin or troglitazone individually (Fig. 5A and C). Despite this concurrent increase, onl
-
Synaptic scaling up is induced within
2023-07-16

Synaptic scaling up is induced within primary visual Icotinib (V1) by brief sensory deprivation (Desai et al., 2002; Lambo and Turrigiano, 2013). Several studies have examined the transcriptional changes within extracts of V1 following visual deprivation protocols (Lachance and Chaudhuri, 2004; Maj
-
1 646 An important observation is that this patient
2023-07-16

An important observation is that this patient has been on ALK inhibitor for more than 4 years (51 months: 27 months on crizotinib+24 months on alectinib and on-going) and there was no evidence of disease progression in the central nervous system. The other potential driver mutation in this patient’s
16742 records 349/1117 page Previous Next First page 上5页 346347348349350 下5页 Last page